- Zacks
After Plunging -40.22% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Simply Wall St.
Should Shareholders Have Second Thoughts About A Pay Rise For Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) CEO This Year?
Key Insights Ginkgo Bioworks Holdings' Annual General Meeting to take place on 13th of June Salary of US$250.0k is part...
- PR Newswire
Ginkgo Bioworks to Participate in Two Conferences in May
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May.
© 2024 Yahoo. All rights reserved.